This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this
class play a crucial role in destroying DNA replication in tumors. We are conducting this
study to determine the Maximum Tolerated Dose of our compound. In addition, we plan to assess
the drug's ability to affect the evolution of malignant gliomas, when given as a capsule,
rather than by intravenous injection.